Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.
- EligibilityCriteria: Inclusion Criteria:  Participants will have asthma diagnosed by a health care provider. Healthy controls are individuals without asthma. Written informed consent  Exclusion Criteria:  Current or recent illness (in the past 4 weeks) Recent asthma exacerbation (past 4 weeks) History of nasal perforation or nasal surgery Nasal polyposis Presence or prior history of cardiac or systemic disease Bleeding disorder, use of systemic anticoagulants, or antiplatelet therapy Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants excluding corticosteroids) Use of tobacco or marijuana in the past 2 months or greater than a 10 pack-year smoking history Currently pregnant or breastfeeding - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult